1039 related articles for article (PubMed ID: 24454709)
41. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
42. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
[TBL] [Abstract][Full Text] [Related]
43. In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios.
Bryant P; Pabst M; Badescu G; Bird M; McDowell W; Jamieson E; Swierkosz J; Jurlewicz K; Tommasi R; Henseleit K; Sheng X; Camper N; Manin A; Kozakowska K; Peciak K; Laurine E; Grygorash R; Kyle A; Morris D; Parekh V; Abhilash A; Choi JW; Edwards J; Frigerio M; Baker MP; Godwin A
Mol Pharm; 2015 Jun; 12(6):1872-9. PubMed ID: 25894424
[TBL] [Abstract][Full Text] [Related]
44. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
Singh AP; Sharma S; Shah DK
J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
[TBL] [Abstract][Full Text] [Related]
45. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.
Andreev J; Thambi N; Perez Bay AE; Delfino F; Martin J; Kelly MP; Kirshner JR; Rafique A; Kunz A; Nittoli T; MacDonald D; Daly C; Olson W; Thurston G
Mol Cancer Ther; 2017 Apr; 16(4):681-693. PubMed ID: 28108597
[TBL] [Abstract][Full Text] [Related]
46. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
[TBL] [Abstract][Full Text] [Related]
47. Current methods for the synthesis of homogeneous antibody-drug conjugates.
Sochaj AM; Świderska KW; Otlewski J
Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
[TBL] [Abstract][Full Text] [Related]
48. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
49. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
Cheng X; Li J; Tanaka K; Majumder U; Milinichik AZ; Verdi AC; Maddage CJ; Rybinski KA; Fernando S; Fernando D; Kuc M; Furuuchi K; Fang F; Uenaka T; Grasso L; Albone EF
Mol Cancer Ther; 2018 Dec; 17(12):2665-2675. PubMed ID: 30262588
[TBL] [Abstract][Full Text] [Related]
50. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
Ohri R; Bhakta S; Fourie-O'Donohue A; Dela Cruz-Chuh J; Tsai SP; Cook R; Wei B; Ng C; Wong AW; Bos AB; Farahi F; Bhakta J; Pillow TH; Raab H; Vandlen R; Polakis P; Liu Y; Erickson H; Junutula JR; Kozak KR
Bioconjug Chem; 2018 Feb; 29(2):473-485. PubMed ID: 29425028
[TBL] [Abstract][Full Text] [Related]
51. [Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology].
Liang XJ; Gong LY; Zhou F; Zhou DM; Zhu JJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 51(5):797-804. PubMed ID: 31624380
[TBL] [Abstract][Full Text] [Related]
52. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
53. Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer.
Gregson SJ; Pugh K; Patel N; Afif-Rider S; Vijayakrishnan B; Santos K; Riedl J; Hutchinson I; Kang GD; Chooi KP; Beard R; Adams L; Barry CS; Ball K; Masterson LA; McFarlane M; Hartley JA; Howard PW
Mol Cancer Ther; 2022 Sep; 21(9):1439-1448. PubMed ID: 35793464
[TBL] [Abstract][Full Text] [Related]
54. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
55. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
[TBL] [Abstract][Full Text] [Related]
56. Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios.
Clardy SM; Uttard A; Du B; Catcott KC; Lancaster KL; Ditty E; Sadowsky J; Zurita J; Malli N; Qin L; Bradley SP; Avocetien K; Carter T; Kim D; Nazzaro M; Xu L; Pillow TH; Zacharias NT; Lewis GD; Rowntree RK; Iyengar R; Lee DH; Damelin M; Toader D; Lowinger TB
Mol Cancer Ther; 2024 Jan; 23(1):84-91. PubMed ID: 37774393
[TBL] [Abstract][Full Text] [Related]
57. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
[TBL] [Abstract][Full Text] [Related]
58. Site-specific antibody drug conjugates for cancer therapy.
Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
[TBL] [Abstract][Full Text] [Related]
59. Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads.
Puthenveetil S; Loganzo F; He H; Dirico K; Green M; Teske J; Musto S; Clark T; Rago B; Koehn F; Veneziale R; Falahaptisheh H; Han X; Barletta F; Lucas J; Subramanyam C; O'Donnell CJ; Tumey LN; Sapra P; Gerber HP; Ma D; Graziani EI
Bioconjug Chem; 2016 Aug; 27(8):1880-8. PubMed ID: 27412791
[TBL] [Abstract][Full Text] [Related]
60. Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells.
Chiang ZC; Chiu YK; Lee CC; Hsu NS; Tsou YL; Chen HS; Hsu HR; Yang TJ; Yang AS; Wang AH
PLoS One; 2020; 15(9):e0239813. PubMed ID: 32986768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
